Jubilant Life Sciences earmarks Rs 550 crore capital expenditure in FY19

20 Aug 2018 Evaluate

Jubilant Life Sciences has earmarked Rs 550 crore for capital expenditure (capex) in the current financial year. The company is planning to invest about Rs 300 crore in Research and Development (R&D) and Rs 550 crore in capital expenditure during the year in order to meet the increased demand of its business.

The company will continue its efforts to strengthen its balance sheet by improving financial ratios and reducing debt.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Jubilant Pharmova Share Price

954.65 -13.60 (-1.40%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×